<DOC>
	<DOCNO>NCT00097526</DOCNO>
	<brief_summary>This study multicenter , open-label , postmarketing surveillance study . The substudy collect information BMD adolescents young adult GHD Turner syndrome complete GH treatment statural indication .</brief_summary>
	<brief_title>Bone Mineral Density ( BMD ) Adolescents With Growth Hormone Deficiency ( GHD )</brief_title>
	<detailed_description />
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Turner Syndrome</mesh_term>
	<mesh_term>Gonadal Dysgenesis</mesh_term>
	<mesh_term>Primary Ovarian Insufficiency</mesh_term>
	<mesh_term>Dwarfism</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Bone age least 15 year girls least 16 year boys within 6 month obtain DXA scan Previous enrollment NCGS core study , 85036 Tanner Stage 4 great Either spontaneous induce puberty Subjects plan terminate GH treatment statural purpose one follow reason : epiphyseal fusion , slow growth rate indicate near adult height reach , satisfied current height Current therapy non Genentech GH product Pregnancy ( avoid exposure low level radiation DXA scanner ) Bilateral hip replacement Weight &gt; 130 kg ( 286 lb . )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Growth Hormone Deficiency</keyword>
</DOC>